Journal of Neuro-Oncology

, Volume 80, Issue 1, pp 1–7 | Cite as

Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression

  • Katariina Korhonen
  • Tiina Salminen
  • Jani Raitanen
  • Anssi Auvinen
  • Jorma Isola
  • Hannu Haapasalo
Laboratory Investigation

Abstract

The female predominance in meningioma incidence and association between meningioma and breast cancer suggest that growth of meningiomas is hormone-dependent. There are several discrepancies in literature about the proliferative effect of sex hormones on meningiomas. This study aims to evaluate the hormone receptor status of meningiomas and assess its relation to age, sex, histological grade, recurrence, and proliferation activity. The material was based on consecutive patients operated for meningioma at Tampere University Hospital in 1989–1999. The occurrence of progesterone, estrogen and androgen receptor in patients with primary and recurrent meningiomas was studied immunohistochemically by using specific monoclonal antibodies. Hormonal status was determined in 510 tumor samples. 443 samples were from primary meningiomas and 67 from recurrent tumors. Of the␣samples, 455 were benign (WHO grade I), 49 atypical (grade II), and 6 malignant (grade III). Of the primary tumor samples, 88% were progesterone receptor positive, 40% were positive for estrogen and 39% for androgen receptors. Grade I meningiomas had significantly higher incidence for estrogen and androgen receptors than higher grade meningiomas. Estrogen positive tumor samples had significantly higher proliferation index than estrogen negative samples. No difference in expression of sex hormone receptors was observed by sexes or age group. Estrogen and androgen receptors may have more influence on the pathogenesis of meningiomas than earlier thought. The higher incidence of meningiomas in women can not be␣explained by differences of sex hormone receptor expression.

Keywords

Androgen receptor Estrogen receptor Meningioma MIB-1 Progesterone receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

We thank Sari Toivola, Salla Kolmihaara, Paula Kaukoranta, and Anssi Lagerstedt for their excellent techincal assistance.

References

  1. 1.
    Abramovich CM, Prayson RA (1998) MIB-1 labeling indices benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 29:1420–1427PubMedCrossRefGoogle Scholar
  2. 2.
    Adams EF, Schrell UM, Fahlbusch R, Thierauf P (1990) Hormonal dependency of cerebral meningiomas. Part 2:In vitro effect of steroids, bromocriptine, and epidermal growth factor ofmeningiomas. J Neurosurg 73:750–755PubMedGoogle Scholar
  3. 3.
    Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K (2001) Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 32:970–975PubMedCrossRefGoogle Scholar
  4. 4.
    Bickerstaff ER, Small JM, Guest IA (1958) The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21:89–91PubMedGoogle Scholar
  5. 5.
    Black P, Carroll R, Zhang J (1996) The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir 65(Suppl):50–53Google Scholar
  6. 6.
    Blankenstein MA, Blaauw G, Lamberts SWJ (1984) Progestin and estrogen receptors in human meningioma. Clin Neuropharmacol 7:363–367PubMedGoogle Scholar
  7. 7.
    Bouillot P, Pellissier JF, Devictor B, Graziani N, Bianco N, Grisoli F, Figarella-Branger D (1994) Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 81:765–773PubMedGoogle Scholar
  8. 8.
    Bozzetti C, Camisa R, Nizzoli R, Manotti L, Guazzi A Naldi N, Mazza S (1995) Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. Surg Neurol 43:230–234PubMedCrossRefGoogle Scholar
  9. 9.
    Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H (1993) Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 33:212–218PubMedGoogle Scholar
  10. 10.
    Carrol RS, Glowacka D, Dashner K, Black PM (1993) Progesterone receptor expression in meningiomas. Cancer Res 53:1312–1316Google Scholar
  11. 11.
    Carrol RS, Zhang J, Dashner K, Sar M, Wilson EM, Black P (1995) Androgen receptor expression in meningiomas. J Neurosurg 82:453–460Google Scholar
  12. 12.
    Carrol RS, Zhang J, Dashner K, Black P (1995) Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery 37:92–97CrossRefGoogle Scholar
  13. 13.
    Carroll RS, Zhang J, Black P (1999) Expression of estrogen receptors alpha and beta in human meningiomas. J Neuro-Oncol 42:109–116CrossRefGoogle Scholar
  14. 14.
    Carrol RS, Brown M, Zhang J, DiRenzo J, Font de Mora J, Black PM (2000) Expression of a subset of steroid receptor cofactors is associated with progesterone receptor epression in meningiomas. Clin Cancer Res 6:3570–3575Google Scholar
  15. 15.
    Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363PubMedCrossRefGoogle Scholar
  16. 16.
    Christensen HC, Kosteljanetz M, Johansen C (2003) Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 52:1327–1334PubMedCrossRefGoogle Scholar
  17. 17.
    Custer BS, Koepsell TD, Mueller BA (2002) The associaton between breast carcinoma and meningioma in women. Cancer 94:1626–1635PubMedCrossRefGoogle Scholar
  18. 18.
    Fewings PE, Battersby RD, Timperley WR (2000) Long-term follow-up of progesterone receptor status in benign meningioma: a prognonstic indicator of recurrence? J Neurosurg 92:401–405PubMedGoogle Scholar
  19. 19.
    Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsen JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neuro-oncol 15:75–77CrossRefGoogle Scholar
  20. 20.
    Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861–866PubMedGoogle Scholar
  21. 21.
    Hana V, Murphy LJ (1994) Interdependence of epidermal growth factor and insulin-like growth factor-I expression in the mouse uterus. Endocrinology 135:107–112PubMedCrossRefGoogle Scholar
  22. 22.
    Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120PubMedGoogle Scholar
  23. 23.
    Hsu DW, Efird JT, Hedley-Whyte ET (1998) MIB-1 (Ki-67) index and transfoming growth factor-alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol App Neurobiology 24:441–452CrossRefGoogle Scholar
  24. 24.
    Jhawar BS, Fuchs CS, Colditz GA, Stamper MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853PubMedCrossRefGoogle Scholar
  25. 25.
    Jääskeläinen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233–242PubMedCrossRefGoogle Scholar
  26. 26.
    Karamitopoulou E, Perentes E, Tolnay M, Probst A (1998) Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29:140–145PubMedCrossRefGoogle Scholar
  27. 27.
    Khalid H (1994) Immunohistochemical study of estrogen receptor related antigen, progesterone and estrogen receptors in human intracranial meningiomas. Cancer 74:679–685PubMedCrossRefGoogle Scholar
  28. 28.
    Kleihues P, Burger PC, Scheithauer B (1993) The new WHO classification of brain tumors. Brain Pathol 3:255–268PubMedGoogle Scholar
  29. 29.
    Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 7:844–847CrossRefGoogle Scholar
  30. 30.
    Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280–290PubMedCrossRefGoogle Scholar
  31. 31.
    Lamberts SW, Tange HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H (1992) Mifepristone (RU486) treatment of meningiomas. J Neurol Neurosurg Psychiat 55:486–490PubMedCrossRefGoogle Scholar
  32. 32.
    Marks SM, Whitewell HL, Lye RH (1986) Recurrence of meningiomas after operation. Surg Neurol 25:436–440PubMedCrossRefGoogle Scholar
  33. 33.
    Markwalder TM, Seiler RW, Zava DT (1985) Antiestrogenic therapy of meningiomas- a pilot study. Surg Neurol 24:245–249PubMedCrossRefGoogle Scholar
  34. 34.
    Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T (1994) Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80:527–534PubMedGoogle Scholar
  35. 35.
    Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, et al (1996) Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91:504–510PubMedCrossRefGoogle Scholar
  36. 36.
    Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN (1993) Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 78:456–462PubMedGoogle Scholar
  37. 37.
    Miller RE (1986) Breast cancer and meningioma. J Surg Oncol 31:182–183PubMedGoogle Scholar
  38. 38.
    Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K (1995) Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 37:478–483PubMedGoogle Scholar
  39. 39.
    Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The natural history of incidental meningiomas. Neurosurgery 53:62–71PubMedCrossRefGoogle Scholar
  40. 40.
    Nakasu S, Hirano A, Shimura T, Llena JF (1987) Incidental meningiomas in autopsy study. Surg Neurol 27:319–322PubMedCrossRefGoogle Scholar
  41. 41.
    Nakasu S, Nakajima M, Matsumura K, Nakasu Y, Handa J (1995) Meningioma: proliferative potential and clinicoradiological features. Neurosurgery 37:1049–1055PubMedGoogle Scholar
  42. 42.
    Olson JJ, Beck DW, Schlechte J, Loh P-M (1986) Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99–107PubMedGoogle Scholar
  43. 43.
    Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, et al (2000) Regression of a presumed meningioma with the antiestrogen agent mepitiostane: case report. J Neurosurg 93:132–135PubMedCrossRefGoogle Scholar
  44. 44.
    Perrot-Applanat M, Groyer-Picard MT, Kujas M (1992) Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir 115:20–30CrossRefGoogle Scholar
  45. 45.
    Reynolds RK, Talavera F, Roberts JA, Hopkins MP, Menon KMJ (1990) Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures. Gynecol Oncol 38:396–406PubMedCrossRefGoogle Scholar
  46. 46.
    Roelvinck NCA, Kamphorst W, van Alphen HAM, Rao R (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215Google Scholar
  47. 47.
    Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M (2004) The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 57:1033–1037PubMedCrossRefGoogle Scholar
  48. 48.
    Rubinstein AB, Loven D, Geier A, Reichental E, Gadoth N (1994) Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 81:184–187PubMedGoogle Scholar
  49. 49.
    Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola J, Helin HJ (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275–282PubMedCrossRefGoogle Scholar
  50. 50.
    Schoenberg BS, Christine BW, Wisnant JP (1975) Nervous system neoplasms and primary malignances of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712PubMedGoogle Scholar
  51. 51.
    Schrell UMH, Adams EF, Fahlbusch R, Greb R, Jirikowski G, Prior R, Ramalho-Ortigao FJ (1990) Hormonal dependency of cerebral meningiomas. Part 1: female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. J Neurosurg 73: 743–749PubMedGoogle Scholar
  52. 52.
    Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink HK, Roosen K (1997) Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas. Neurosurgery 41:1152–1159PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Katariina Korhonen
    • 1
  • Tiina Salminen
    • 2
  • Jani Raitanen
    • 2
  • Anssi Auvinen
    • 2
  • Jorma Isola
    • 3
  • Hannu Haapasalo
    • 4
  1. 1.Department of NeurosurgeryUniversity Hospital of TurkuTurkuFinland
  2. 2.School of Public HealthUniversity of TampereTampereFinland
  3. 3.Laboratory of cancer biologyInstitute of Medical Technology, University of Tampere and Tampere University HospitalTampereFinland
  4. 4.Department of Pathology, Centre for Laboratory MedicineTampere University HospitalTampereFinland

Personalised recommendations